Lipocine Inc. (NASDAQ: LPCN) is a biopharmaceutical company focused on oral drug delivery of poorly bioavailable molecules, operating from Salt Lake City, Utah. Revenue comes from license fees, royalty payments, and milestone payments from third-party licensees, not from direct product sales. As of the 10-K filed March 10, 2026, Lipocine reported generating $55.1 million in cumulative revenue since inception through December 31, 2025, entirely from licensing and collaboration agreements. The company's sole FDA-approved product is TLANDO, an oral testosterone replacement therapy (TRT), licensed to partners in South Korea (SPC Korea Limited), the Gulf Cooperation Council countries (Pharmalink), and Brazil (Aché). Lipocine retains commercialization rights for TLANDO in other territories outside those agreements and the U.S. and Canada. The clinical pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, LPCN 2401 for body composition in GLP-1 agonist users, and LPCN 1148 for decompensated cirrhosis. Cash used in operating activities was $9.8 million for the year ended December 31, 2025, versus $1.2 million for the year ended December 31, 2024.

Revenue model

License fees, royalties on net sales, and regulatory milestone payments from regional licensees of TLANDO. No product sales revenue generated as of December 31, 2025. Equity issuances under at-the-market agreements provide supplemental funding, including $2.9 million from 806,878 shares sold in FY2025.

Products and services

TLANDO: FDA-approved oral testosterone replacement therapy, licensed regionally to SPC Korea Limited (South Korea), Pharmalink (GCC countries), and Aché (Brazil). Pipeline candidates: LPCN 1154 (postpartum depression), LPCN 2201 (major depressive disorder), LPCN 2101 (epilepsy), LPCN 2203 (essential tremor), LPCN 2401 (body composition in GLP-1 agonist use), LPCN 1148 (decompensated cirrhosis and hepatic encephalopathy), LPCN 1107 (pre-term birth prevention).

Customers and end markets

Licensee partners (SPC Korea Limited, Pharmalink, Aché) are the direct revenue sources. End markets are testosterone-deficient adult males for TRT, and patients in neurological, psychiatric, and hepatic disease indications for pipeline assets. Reimbursement depends on third-party payers including government health programs and private insurers.

Value-chain role

Drug developer and licensor. Lipocine conducts research, formulation development, and regulatory work, then licenses commercialization rights to regional partners who handle sales and distribution. Lipocine supplies product to licensees at agreed transfer prices in some agreements.

Geographic exposure

TLANDO licensed in South Korea (SPC Korea Limited, September 2024), GCC countries including Saudi Arabia, Kuwait, UAE, Qatar, Bahrain, and Oman (Pharmalink, October 2024), and Brazil (Aché, April 2025). U.S. and Canada rights retained by Lipocine. Corporate headquarters in Salt Lake City, Utah, under lease extended through February 28, 2027.

Source: SEC 10-K, filed 2026-03-10

Industry: Pharmaceutical Preparations Peers: DMK PHARMACEUTICALS Corp Item 9 Labs Corp. Akari Therapeutics PLC Cognition Therapeutics Inc Opus Genetics Inc Cumberland Pharmaceuticals Inc Endexx Corp Johnson & Johnson Zynerba Pharmaceuticals, Inc.